Calypso and Elekta combine for radiation therapy pact
This article was originally published in Clinica
Calypso Medical Technologies is to integrate its tumour tracking system into Elekta’s radiotherapy technology. The two firms have entered a development agreement which will see them jointly produce technology designed to treat prostate cancer, as well as other cancers that are difficult to treat with radiation targets such as pancreas and lung. The Calypso System is the only commercially-available real-time tumour tracking device, while Elekta’s Synergy and Precise linear accelerators deliver intensity-modulated radiotherapy. Financial terms of the collaboration were not disclosed.
You may also be interested in...
Alere’s professional diagnostics business helped the firm record overall revenue growth in the fourth quarter of 2010, offsetting a fall in influenza-based sales in North America.
Integra LifeSciences has gained exclusive worldwide rights from Stout Medical to develop and commercialise an expandable interbody fusion device.
Gen-Probe recently launched its Panther automated molecular diagnostics system in Europe with the aim of bringing another dimension to its product portfolio. Joseph Harvey met the firm’s CEO, Carl Hull, at the launch of the product in Frankfurt to find how high the firm has set its sights in the molecular diagnostics sector and how it is going to achieve its goals